Advanced search
Publication Cover
Journal of Dermatological Treatment Volume 29, 2018 - Issue sup2: Safety of secukinumab in moderate-severe psoriasis and psoriatic arthritis: evidences from real-life experiences
Submit an article Journal homepage
1,439
Views
11
CrossRef citations to date
0
Altmetric
Safety of secukinumab on Psoriasis: evidences from real life experiences

Successful therapy of plaque-type psoriasis with secukinumab in patients with multiple comorbidities treated with previous biologic therapies

Claudia LasagniDermatology Unit, Azienda Ospedaliero-Universitaria Policlinico di Modena, Modena, ItalyCorrespondence[email protected]
View further author information
,
Laura BigiDermatology Unit, Azienda Ospedaliero-Universitaria Policlinico di Modena, Modena, ItalyView further author information
,
Andrea ContiDermatology Unit, Azienda Ospedaliero-Universitaria Policlinico di Modena, Modena, ItalyView further author information
&
Giovanni PellacaniDermatology Unit, Azienda Ospedaliero-Universitaria Policlinico di Modena, Modena, ItalyView further author information
Pages 5-8 | Received 15 Feb 2018, Accepted 28 Sep 2018, Published online: 25 Dec 2018

References

  • Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol. 2014;70:512–516. Epub 2014/01/07.
  • AbuHilal M, Walsh S, Shear N. The Role of IL-17 in the pathogenesis of psoriasis and update on IL-17 inhibitors for the treatment of plaque psoriasis. J Cutan Med Surg. 2016;20:509–516. Epub 2016/05/22.
  • Rothstein B, Gottlieb A. Secukinumab for treating plaque psoriasis. Expert Opin Biol Ther. 2016;16:119–128. Epub 2015/11/19.
  • Roman M, Madkan VK, Chiu MW. Profile of secukinumab in the treatment of psoriasis: current perspectives. Ther Clin Risk Manag. 2015;11:1767–1777. Epub 2015/12/15.
  • Kircik L, Fowler J, Weiss J, et al. Efficacy of secukinumab for moderate-to-severe head and neck psoriasis over 52 weeks: pooled analysis of four phase 3 studies. Dermatol Ther (Heidelb). 2016;6:627–638. Epub 2016/08/31.
  • Malakouti M, Jacob SE, Anderson NJ. Treatment challenges in the management of moderate-to-severe plaque psoriasis - role of secukinumab. CCID. 2016;9:347–355. Epub 2016/10/
  • van de Kerkhof PC, Griffiths CE, Reich K, et al. Secukinumab long-term safety experience: a pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis. J Am Acad Dermatol. 2016;75:83–98 e4. Epub 2016/05/18.
  • Cannizzaro MV, Franceschini C, Esposito M, et al. Hepatitis B reactivation in psoriasis patients treated with anti-TNF agents: prevention and management. PTT. 2017;7:35–40.
  • Mori S, Fujiyama S. Hepatitis B virus reactivation associated with antirheumatic therapy: risk and prophylaxis recommendations. WJG. 2015;21:10274–10289. Epub 2015/10/01.
  • Chang S, Chambers CJ, Liu FT, et al. Successful treatment of psoriasis with ustekinumab in patients with multiple sclerosis. Dermatol Online J. 2015;21:Epub 2015/10/06.
  • Blauvelt A. Safety of secukinumab in the treatment of psoriasis. Expert Opin Drug Saf. 2016;15:1413–1420. Epub 2016/08/23.
  • Du W, Zhen J, Zeng Z, et al. Expression of interleukin-17 associated with disease progression and liver fibrosis with hepatitis B virus infection: IL-17 in HBV infection. Diagn Pathol. 2013;8:40.
  • Winthrop K, Mariette X, Silva J, et al. ESCMID study group for infections in compromised hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors). Clin Microbiol Infect. 2018;24:S21–SS4.
  • Menter A, Cather JC, Jarratt M, et al. efficacy of secukinumab on moderate-to-severe plaque psoriasis affecting different body regions: a pooled analysis of four phase 3 studies. Dermatol Ther (Heidelb). 2016;6:639–647. Epub 2016/09/01.
  • Bissonnette R, Luger T, Thaci D, et al. Secukinumab sustains good efficacy and favourable safety in moderate to severe psoriasis up to 3 years of treatment: results from a double-blind extension study. Br J Dermatol. 2017;177:1033–1042.
  • Smith CH, Jabbar-Lopez ZK, Yiu ZZ, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017. Br J Dermatol. 2017;177:628–636.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.